Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Forrester

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Science (New York, N.Y.)|March 12, 2016
Schedule-dependent interaction between anticancer treatmentsSheng-Hong Chen, William Forrester, Galit Lahav
Cancers|April 13, 2024
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple MyelomaBasudev Chowdhury, Swati Garg, Wei Ni, et al.
Nature Chemical Biology|June 24, 2020
Manumycin polyketides act as molecular glues between UBR7 and P53Yosuke Isobe, Mikiko Okumura, Lynn M McGregor, et al.
Nature Medicine|June 13, 2018
p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cellsRobert J Ihry, Kathleen A Worringer, Max R Salick, et al.
Blood Cancer Journal|July 19, 2022
BRD9 degraders as chemosensitizers in acute leukemia and multiple myelomaEllen Weisberg, Basudev Chowdhury, Chengcheng Meng, et al.
Cancer Research|June 26, 2026
BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial SarcomaJinxiu Li, Mary L Nelson, Li Li, et al.
Cell|July 29, 2017
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi ScreeningE Robert McDonald, Antoine de Weck, Michael R Schlabach, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Science (New York, N.Y.)|March 12, 2016
Schedule-dependent interaction between anticancer treatmentsSheng-Hong Chen, William Forrester, Galit Lahav
Cancers|April 13, 2024
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple MyelomaBasudev Chowdhury, Swati Garg, Wei Ni, et al.
Nature Chemical Biology|June 24, 2020
Manumycin polyketides act as molecular glues between UBR7 and P53Yosuke Isobe, Mikiko Okumura, Lynn M McGregor, et al.
Nature Medicine|June 13, 2018
p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cellsRobert J Ihry, Kathleen A Worringer, Max R Salick, et al.
Blood Cancer Journal|July 19, 2022
BRD9 degraders as chemosensitizers in acute leukemia and multiple myelomaEllen Weisberg, Basudev Chowdhury, Chengcheng Meng, et al.
Cancer Research|June 26, 2026
BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial SarcomaJinxiu Li, Mary L Nelson, Li Li, et al.
Cell|July 29, 2017
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi ScreeningE Robert McDonald, Antoine de Weck, Michael R Schlabach, et al.
Pageof 1